A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Latest Information Update: 09 May 2024
At a glance
- Drugs Elebsiran (Primary) ; Tobevibart (Primary) ; Peginterferon alfa
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms MARCH
- Sponsors Vir Biotechnology
- 02 May 2024 According to a Vir Biotechnology media release, Part B of this trial is fully enrolled
- 22 Mar 2024 According to a Brii biosciences media release, additional data will be presented in the second quarter of 2024 and complete 24-week treatment data are expected in the fourth quarter of 2024.
- 14 Nov 2023 End of treatment (EOT) results after 24 weeks of therapy (MARCH STUDY PART B) presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases